SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Livdelzi

GILD·GILEAD SCIENCES, INC.
BULLISH
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially launched in the US (August 2024) and EU (2025).
Why 4/10
Livdelzi is already approved and commercially launched with no pending regulatory decision or dated binary catalyst in the next ~12 months. The Phase 3 IDEAL trial already read out positive in June 2026. While Livdelzi is a meaningful growth driver for Gilead's liver disease portfolio, Gilead is a large-cap biotech with multiple revenue pillars (HIV, oncology), so this single drug does not drive a binary outcome for the stock.
Actionable Insight BULLISH

Watch for any announcement regarding conversion of Livdelzi's accelerated approval to traditional approval based on the positive IDEAL trial data, which could serve as a label-strengthening catalyst. Also monitor quarterly liver disease portfolio sales trends for Livdelzi's commercial trajectory, particularly as it captures share following Ocaliva's US market withdrawal. The next hard catalyst for Gilead overall is the December 23, 2026 PDUFA for anito-cel (a different drug), not Livdelzi.

Price Chart

Loading chart...

Executive Summary

Livdelzi (seladelpar) is an oral PPAR-delta agonist approved by the FDA in August 2024 for primary biliary cholangitis (PBC), a rare autoimmune liver disease. Gilead acquired the drug through its $4.3 billion purchase of CymaBay Therapeutics in early 2024. The drug has generated strong clinical data from two Phase 3 trials (RESPONSE and IDEAL) and is driving growth in Gilead's liver disease portfolio, which posted $927 million in Q3 2026 sales (up 13% year-over-year). Livdelzi competes with Ipsen's Iqirvo (elafibranor) in the second-line PBC market, while the older competitor Ocaliva was withdrawn from the US market in November 2025. As an already-approved, commercially launched product within a diversified large-cap biotech, Livdelzi contributes to Gilead's growth but does not represent a binary catalyst for the stock.

How It Works

Livdelzi is an oral pill that activates a cellular receptor called PPAR-delta, which helps regulate bile acid production and reduce inflammation in the liver. In primary biliary cholangitis (PBC), a rare autoimmune disease where bile ducts are gradually destroyed, the drug works by lowering toxic bile acid levels and easing the itching (pruritus) that many patients experience.

Trial Status

Livdelzi received FDA accelerated approval on August 14, 2024 based on the Phase 3 RESPONSE trial, which showed 62% of patients achieved the composite biochemical response endpoint at 12 months versus 20% for placebo. A second Phase 3 trial, IDEAL, met its primary endpoint in June 2026, demonstrating statistically significant ALP normalization at 52 weeks in patients with inadequately controlled PBC. The drug also received conditional European marketing authorization in 2025 (branded as Lyvdelzi).

The Two-Sided Case

▲ Bull Case5
Strong clinical data: Livdelzi achieved statistically significant ALP normalization in two Phase 3 trials (RESPONSE and IDEAL), with a favorable safety profile and demonstrated pruritus relief.
Commercial momentum: Liver disease portfolio sales reached $927M in Q3 2026, up 13% YoY, driven by Livdelzi demand. Gilead raised full-year base business guidance in October 2026.
Competitive advantage: The older competitor Ocaliva (obeticholic acid) was withdrawn from the US market in November 2025, removing a major rival and potentially expanding Livdelzi's addressable market.
European expansion: Conditional marketing authorization in the EU (as Lyvdelzi) opens a new geographic market, and NICE review in the UK is underway.
Gilead's commercial infrastructure: As a top-tier biotech with established liver disease sales and marketing capabilities, Gilead can maximize Livdelzi's reach to hepatologists and PBC patients.
▼ Bear Case5
Accelerated approval status: Livdelzi's US approval is conditional on confirmatory data demonstrating clinical benefit (improvement in survival or prevention of liver decompensation), which has not yet been proven.
Competition from Iqirvo: Ipsen's elafibranor (Iqirvo) also received accelerated FDA approval in June 2024 for the same second-line PBC indication, creating direct head-to-head competition for market share.
Pricing and reimbursement pressure: As a second-line therapy in a rare disease, Livdelzi faces ongoing payer scrutiny and prior authorization requirements that could limit uptake.
Dilution risk: The $4.3 billion CymaBay acquisition represents a significant upfront cost that may take years to recoup through Livdelzi sales.
Insider selling: Multiple Gilead executives (CEO, CFO, other officers) have been selling shares under 10b5-1 plans in recent months, though these are pre-planned trades.

Upcoming Catalysts

  • No upcoming PDUFA date or pivotal readout specifically for Livdelzi has been identified. The next major catalyst for Gilead overall is the December 23, 2026 PDUFA for anito-cel (a CAR-T therapy for multiple myeloma), not for Livdelzi.
  • Potential label expansion or conversion from accelerated to traditional FDA approval based on the positive IDEAL trial data, though no specific date has been announced.
  • Continued commercial execution and quarterly sales growth as Livdelzi gains share in the PBC market following Ocaliva's withdrawal.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GILEAD SCIENCES, INC. 8-K GILD ·Originating report

Sources · 10

Hover a chip for the title
1 gilead.com2 gilead.com3 gilead.com4 gilead.com5 gilead.com6 accessdata.fda.gov7 biopharmadive.com8 trialfriend.com9 drugs.com10 nejm.org